
Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.
Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.
An expert on breast cancer reviews currently available tests for ESR1 mutations and provides clinical insights on best practices for testing.
Stephanie L. Graff, MD, provides an overview of ESR1 mutations in ER+/HER2- metastatic breast cancer, highlighting their prevalence, clinical implications, and challenges.
Published: August 18th 2025 | Updated: August 25th 2025
Published: August 19th 2025 | Updated: August 22nd 2025
Published: June 6th 2025 | Updated: August 18th 2025
Published: June 27th 2025 | Updated: July 1st 2025
Published: February 20th 2025 | Updated: February 21st 2025
Published: January 16th 2025 | Updated: January 29th 2025
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.